Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

Dr Kelly study for many years CCR5

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
misiu143 Member Profile
Member Level 
Followed By 86
Posts 9,017
Boards Moderated 1
Alias Born 12/18/03
160x600 placeholder
CytoDyn to conduct two COVID-19 trials in Brazil Seeking Alpha - 5/5/2021 6:25:40 AM
CytoDyn provides updates on leronlimab HIV extension arm; to hold webcast on May 5 on multiple initiatives Seeking Alpha - 5/3/2021 9:46:59 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/29/2021 4:32:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/21/2021 6:28:13 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/21/2021 4:31:54 PM
CytoDyn initiates rolling submission of leronlimab in COVID-19 to Canada regulator Seeking Alpha - 4/19/2021 6:54:58 AM
CytoDyn executes supply and distribution agreement with Chiral Pharma Seeking Alpha - 4/15/2021 9:34:25 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/12/2021 4:31:04 PM
CytoDyn completes enrollment in COVID-19 long-hauler trial Seeking Alpha - 4/9/2021 6:59:31 AM
CytoDyn updates on leronlimab-treated COVID-19 patient Seeking Alpha - 4/5/2021 11:51:19 AM
CytoDyn to provide full update on its activities on April 6 Seeking Alpha - 4/1/2021 6:19:48 AM
CytoDyn files new protocol with FDA for 4 doses of leronlimab for critical COVID-19 Seeking Alpha - 4/1/2021 6:13:14 AM
CytoDyn’s leronlimab reduces mortality by 82% at 14 days in critically ill COVID-19 patients Seeking Alpha - 3/30/2021 7:08:56 AM
Philippines OKs use of CytoDyn's leronlimab in COVID-19 Seeking Alpha - 3/29/2021 6:30:52 AM
Nextech AR (OTCQB: NEXCF) Doubling Sales - Emerging Growth Report InvestorsHub NewsWire - 3/24/2021 6:45:37 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 3/18/2021 7:46:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/16/2021 8:31:13 AM
CytoDyn promotes from within for COO role Seeking Alpha - 3/16/2021 6:03:45 AM
Nextech AR (OTCQB: NEXCF) $13 million Deal, The Next Short Squeeze InvestorsHub NewsWire - 3/11/2021 7:53:20 AM
Enrollment underway in CytoDyn’s long-haulers COVID-19 trial Seeking Alpha - 3/11/2021 5:49:54 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/8/2021 5:28:38 PM
CytoDyn to release CD12 trial data on March 8 Seeking Alpha - 3/8/2021 6:34:51 AM
CytoDyn to file for rolling review of leronlimab in COVID-19 in U.S., U.K. and Canada Seeking Alpha - 3/7/2021 11:56:10 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 3/3/2021 5:23:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/2/2021 8:32:38 AM
misiu143 Member Level  Tuesday, 05/04/21 06:21:32 PM
Re: Scooter McCabe post# 163484
Post # of 164279 
Dr Kelly study for many years CCR5 and leronlimab, being in CYDY now..

And he is a physician to start with ..needed to finish medical school..

For me to be a specialist in pediatrics I needed to do residency for 3 years after my medical school , Did it in NYC.
and then to be also a dermatologists , another 3 years residency in dermatology after that..Did it in NYC ..
So total 6 years after the medical school..

And being in CYDY for over 5 years and study and reading a lot ,
I believe that I may also give a lectures with good understanding , in HIV , cancers and covid , and believe me , I will not be to bad...

For so many years being and evaluating leronlimab I believe dr Kelly is better then most,
except VERY few , like Dr Patterson who study only CCR5 for about 25 years..

There are very, very few like that. With that narrow specialty..

All IMO.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences